Ghent University Academic Bibliography

Your filters: cql: author="Billiet, Charlotte" or (type any "bookEditor issueEditor" and editor="Billiet, Charlotte")

Add to list
- Journal Article
- A1
- open access
Nonpharmacological interventions for managing the dyspnea-fatigue-physical/role functioning symptom cluster in lung cancer patients : a systematic review

Clara Leyns (UGent) , Cassandra Van Boterdael, Ellen Baele (UGent) , Lindsay Poppe (UGent) , Charlotte Billiet, Renée Bultijnck (UGent) , Maarten Lambrecht, Yolande Lievens (UGent) and Elke Rammant (UGent)

(2024) EUROPEAN JOURNAL OF CANCER CARE. 2024. p.1-24
Add to list
- Journal Article
- A1
- open access
Parameterisation of respiratory impedance in lung cancer patients from forced oscillation lung function test

Maria Ghita, Charlotte Billiet, Dana Copot (UGent) , Dirk Verellen (UGent) and Clara Ionescu (UGent)

(2023) IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING. 70(5). p.1587-1598
Add to list
Local anomalous drug diffusion at healthy-cancer tissue surface and data-driven tumor growth model prediction

Maria Ghita, Dana Copot (UGent) , Charlotte Billiet, Dirk Verellen (UGent) and Clara Ionescu (UGent)

(2023) 2023 AMERICAN CONTROL CONFERENCE, ACC. In Proceedings of the American Control Conference p.2867-2872
Add to list
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens (UGent) , Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, et al.

(2023) LANCET ONCOLOGY. 24(3). p.e121-e132
Add to list
- Journal Article
- A1
- open access
Model calibration of pharmacokinetic-pharmacodynamic lung tumour dynamics for anticancer therapies

Maria Ghita, Charlotte Billiet, Dana Copot (UGent) , Dirk Verellen (UGent) and Clara Ionescu (UGent)

(2022) JOURNAL OF CLINICAL MEDICINE. 11(4).
Add to list
Completeness of reporting oligometastatic disease characteristics in literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature

Daan Nevens, Aurélien Jongen, Isabelle Kindts, Charlotte Billiet, Pieter Deseyne, Ines Joye, Yolande Lievens (UGent) and Matthias Guckenberger

(2022) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 114(4). p.587-595
Add to list
- Conference Paper
- P1
- open access
Lung tumor growth modeling in patients with NSCLC undergoing radiotherapy

Maria Ghita, Vasudha Chandrashekar, Dana Copot (UGent) , Charlotte Billiet, Dirk Verellen (UGent) and Clara Ionescu (UGent)

(2021) IFAC PAPERSONLINE. 54(15). p.233-238
Add to list
- Journal Article
- A1
- open access
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, et al.

(2020) BMC CANCER. 20(1).
Add to list
- Journal Article
- A1
- open access
A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)

Carole Mercier, Piet Dirix, Piet Ost (UGent) , Charlotte Billiet, Ines Joye, Peter Vermeulen, Yolande Lievens (UGent) and Dirk Verellen

(2019) BMC CANCER. 19(1).

Academic Bibliography

Nonpharmacological interventions for managing the dyspnea-fatigue-physical/role functioning symptom cluster in lung cancer patients : a systematic review

Parameterisation of respiratory impedance in lung cancer patients from forced oscillation lung function test

Local anomalous drug diffusion at healthy-cancer tissue surface and data-driven tumor growth model prediction

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Model calibration of pharmacokinetic-pharmacodynamic lung tumour dynamics for anticancer therapies

Completeness of reporting oligometastatic disease characteristics in literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature

Lung tumor growth modeling in patients with NSCLC undergoing radiotherapy

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)

Contents

Support

Contact